Dementia, a progressive disorder that impacts memory and independence, affects millions globally. While many are aware of ...

Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.

For many years, platinum-based chemotherapy has been one of the mainstays for advanced testicular cancer. Painful peripheral ...

However, a recent study from Sunnybrook Research Institute offers some hope. Researchers found that a type of diabetes ...

The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for subcutaneous (SC) maintenance dosing of lecanemab-irmb for the treatment of Alzheimer disease (AD) in ...

As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...

Leqembi's subcutaneous dosing allows Alzheimer's patients to administer weekly treatment at home in 15 seconds ... with Mild ...

Study Identifies Potential New Drug for Parkinson's-Related Cognitive Decline, Dementia Nov. 19 ... which could lead to treatments for the cognitive symptoms of Parkinson's ...

Before treatment, patients need a diagnosis confirmed ... based on a blood test as the enrolment criterion for dementia drug trials. That could pave the way for those blood tests, which look ...

Cognitive profiles for early diagnosis of Dementia with Lewy bodies (DLB) have been outlined in a new study. Although DLB is the second most common neurodegenerative dementia following Alzheimer's ...

SHENZHEN, CHINA, Jan. 08, 2025 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce ...

ZUNVEYL will further diversify our Group’s innovative drug product matrix and synergize with ... efficacy and demonstrated long-term clinical benefit in the treatment of mild-to-moderate dementia of ...